ALSO READNews digest: 2G verdict, SGX move, RBI report and more News digest: Election results, stressed assets, FRDI Bill, and more News digest: NTPC plant explosion, plush hotel rooms in sky, and more News digest: IBC, Apple's India head, Maruti overtakes HUL, and more News digest: Pharma firms face price heat, markets log new highs, and more
Taxing times for IPOs: LTCG tax prompts issuers to expedite market launch The reintroduction of the long-term capital gains (LTCG) tax has placed companies coming up with initial public offerings (IPOs) in a quandary. According to sources, about half-a-dozen companies are planning to launch their IPOs before the end of this fiscal year to avoid the tax. However, the downturn in the stock market provides little comfort to bankers and issuers over listing. Read more Market slide continues as FIIs press sell button on rising US bond yields Indian and global equities extended the sell-off on Monday, as investors’ risk appetite continued to wane after US bond yields hit a four-year high, raising speculation that the Federal Reserve will raise policy rates more aggressively. Read more Tata Motors turns profitable at standalone level after five quarters Tata Motors, the country’s biggest truckmaker, is back in black at a standalone level in the third quarter, helped by sharp growth in revenues (led by volumes) and cost reduction.
The company had incurred losses at a standalone level in the five preceding quarters. Read more Dr Reddy's Labs acquiring products but not marketing most of them Indian drug manufacturer Dr Reddy's Laboratories is yet to translate a majority of product acquisitions it made between 2014 and 2016 into commercial opportunities. Some products were stuck over approvals, the company said, while a few others remained in the realm of the firm’s long-term opportunities. According to a latest filing with the US Securities and Exchange Commission, Dr Reddy's has so far been able to take products to the stage of commercial launch in just four out of nine asset acquisitions. The firm had spent a staggering Rs 42.17 billion on these buys. Read more